Combination treatment for lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two drugs (QL1706 and bevacizumab) with or without chemotherapy for people with advanced non-squamous lung cancer whose cancer worsened after prior immunotherapy. It may offer a new option for those with low PD-L1 levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage III or IV non-squamous non-small cell lung cancer (a specific type of lung cancer).
- Your cancer got worse during or after prior treatment with an immunotherapy drug (like a PD-1 or PD-L1 blocker).
- Your most recent tumor test shows low PD-L1 levels (less than 1%).
- You have not had more than 1 prior treatment for advanced lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
This trial tests whether adding two newer drugs (benmelstobart and anlotinib) to chemotherapy before radiation works better than radiation alone for stage III non-small cell lung cancer that cannot be surgically removed. The goal is to improve survival and control the cancer.
This trial tests a new combination of drugs (QL1706 plus chemo and bevacizumab) for people with advanced lung cancer that has a specific gene mutation, has stopped responding to targeted therapy, and has high PD-L1 levels. It aims to see if this approach can help when other treatments have stopped working.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new combination of drugs (QL1706, anti-angiogenesis therapy, and chemotherapy) for people with extensive-stage small cell lung cancer who have not received any prior treatment. The goal is to see if this combination works better than standard care.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.